|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
106,253,000 |
Market
Cap: |
1.74(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$14.54 - $34.09 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Beam Therapeutics is a biotechnology company. Co. has identified four development candidates to date: three from its ex vivo platform, with two candidates targeting hemoglobinopathies and one candidate targeting T-cell leukemia, and one from its in vivo platform targeting glycogen storage disease. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
49,624 |
126,973 |
338,512 |
1,492,240 |
Total Sell Value |
$1,015,628 |
$2,422,018 |
$8,024,394 |
$42,794,845 |
Total People Sold |
2 |
6 |
6 |
7 |
Total Sell Transactions |
3 |
9 |
19 |
36 |
End Date |
2025-05-22 |
2025-02-18 |
2024-08-20 |
2023-08-21 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Fmr Corp |
See Remark 1 |
|
2025-07-30 |
4 |
S |
$20.50 |
$991,667 |
I/I |
(48,374) |
2,073,665 |
|
12% |
|
Simon Amy |
Chief Medical Officer |
|
2025-07-03 |
4 |
AS |
$20.12 |
$17,625 |
D/D |
(876) |
64,864 |
|
-11% |
|
Simon Amy |
Chief Medical Officer |
|
2025-07-01 |
4 |
AS |
$16.94 |
$6,336 |
D/D |
(374) |
65,740 |
|
2% |
|
Simon Amy |
Chief Medical Officer |
|
2025-04-02 |
4 |
AS |
$17.73 |
$372,294 |
D/D |
(20,997) |
65,742 |
|
-9% |
|
Ciaramella Giuseppe |
President |
|
2025-04-01 |
4 |
AS |
$18.35 |
$136,418 |
D/D |
(7,434) |
190,216 |
|
-3% |
|
Cavanagh Bethany J |
SVP, Finance and Treasurer |
|
2025-04-01 |
4 |
AS |
$18.35 |
$55,330 |
D/D |
(3,015) |
44,512 |
|
-3% |
|
Simon Amy |
Chief Medical Officer |
|
2025-04-01 |
4 |
AS |
$18.35 |
$175,542 |
D/D |
(9,566) |
86,739 |
|
-3% |
|
Bellon Christine |
Chief Legal Officer |
|
2025-04-01 |
4 |
AS |
$18.35 |
$104,122 |
D/D |
(5,674) |
117,294 |
|
-3% |
|
Evans John M. |
CEO |
|
2025-04-01 |
4 |
AS |
$18.35 |
$562,684 |
D/D |
(30,663) |
986,249 |
|
-3% |
|
Fmr Corp |
|
|
2025-03-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,261,955 |
|
-10% |
|
Evans John M. |
CEO |
|
2025-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
77,500 |
1,016,159 |
|
- |
|
Ciaramella Giuseppe |
President |
|
2025-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
197,650 |
|
- |
|
Cavanagh Bethany J |
SVP, Finance and Treasurer |
|
2025-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
47,527 |
|
- |
|
Simon Amy |
Chief Medical Officer |
|
2025-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
96,305 |
|
- |
|
Bellon Christine |
Chief Legal Officer |
|
2025-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
122,968 |
|
- |
|
Cavanagh Bethany J |
SVP, Finance and Treasurer |
|
2025-02-18 |
4 |
AS |
$35.00 |
$220,045 |
D/D |
(6,287) |
37,527 |
|
-50% |
|
Bellon Christine |
Chief Legal Officer |
|
2025-02-14 |
4 |
AS |
$34.00 |
$340,000 |
D/D |
(10,000) |
102,968 |
|
-47% |
|
Bellon Christine |
Chief Legal Officer |
|
2025-02-14 |
4 |
OE |
$7.22 |
$72,200 |
D/D |
10,000 |
112,968 |
|
- |
|
Evans John M. |
CEO |
|
2025-01-30 |
4/A |
OE |
$0.67 |
$20,100 |
D/D |
30,000 |
968,659 |
|
- |
|
Evans John M. |
CEO |
|
2025-01-30 |
4 |
AS |
$26.75 |
$802,484 |
D/D |
(30,000) |
908,659 |
|
-34% |
|
Bellon Christine |
Chief Legal Officer |
|
2025-01-02 |
4 |
AS |
$24.68 |
$30,628 |
D/D |
(1,241) |
102,968 |
|
-30% |
|
Cavanagh Bethany J |
SVP, Finance and Treasurer |
|
2025-01-02 |
4 |
AS |
$24.68 |
$27,568 |
D/D |
(1,117) |
43,814 |
|
-30% |
|
Emany Sravan Kumar |
Chief Financial Officer |
|
2024-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
80,000 |
|
- |
|
Ciaramella Giuseppe |
President |
|
2024-12-17 |
4 |
OE |
$0.67 |
$35,845 |
D/D |
53,500 |
162,650 |
|
- |
|
Ciaramella Giuseppe |
President |
|
2024-11-06 |
4 |
AS |
$26.36 |
$1,347,050 |
D/D |
(51,110) |
109,150 |
|
-14% |
|
204 Records found
|
|
Page 1 of 9 |
|
|